Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Tuberculosis | Research article

Reducing delays to multidrug-resistant tuberculosis case detection through a revised routine surveillance system

Authors: Basra Esmail Doulla, Stephen Bertel Squire, Eleanor MacPherson, Esther Stanslaus Ngadaya, Beatrice Kemilembe Mutayoba, Ivor Langley

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Implementation of an effective Tuberculosis Routine Surveillance System in low-income countries like Tanzania is problematic, despite being an essential tool for the detection and effective monitoring of drug resistant tuberculosis. Long delays in specimen transportation from the facilities to reference laboratory and results dissemination back to the health facilities, result in poor patient management, particularly where multidrug-resistant tuberculosis disease is present.

Methods

Following a detailed qualitative study, a pilot intervention of a revised Tuberculosis Routine Surveillance System was implemented in Mwanza region, Tanzania. This included the use of rapid molecular methods for the detection of both tuberculosis and drug resistance using Xpert MTB/RIF in some Mwanza sites, the use of Xpert MTB/RIF and Line Probe Assay at the Central Tuberculosis Reference Laboratory, a revised communication strategy and interventions to address the issue of poor form completion. A before and after comparison of the intervention on the number of drug resistant tuberculosis cases identified and the time taken for results feedback to the requesting site was reported.

Results

The revised system for previously treated cases tested at the Central Reference Laboratory was able to obtain the following findings; the number of cases tested increased from 75 in 2016 to 185 in 2017. The times for specimen transportation from health facilities to the reference laboratory were reduced by 22% (from 9 to 7 days). The median time for the district to receive results was reduced by 36% (from 11 to 7 days). Overall the number of drug resistant tuberculosis cases starting treatment increased by 67% (from 12 to 20).

Conclusion

Detection of drug resistance could significantly be enhanced, and delays reduced by introduction of new technologies and improved routine surveillance system, including better communication using mobile applications such as ‘WhatsApp’ and close follow-ups. A larger scale study is now merited to ascertain if these benefits are robust across different contexts.
Literature
1.
go back to reference World Health Organization. Global tuberculosis report. Geneva: World Health Organization; 2017. World Health Organization. Global tuberculosis report. Geneva: World Health Organization; 2017.
4.
go back to reference Ridderhof JC, Van Deun A, Kai MK, Narayanan PR, Aziz MA. Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ. 2007;85:354–9.CrossRef Ridderhof JC, Van Deun A, Kai MK, Narayanan PR, Aziz MA. Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ. 2007;85:354–9.CrossRef
5.
go back to reference Weyer K, Carai S, Nunn P. Viewpoint TB diagnostics: What does the world really need? J Infect Dis. 2011;204(SUPPL):4. Weyer K, Carai S, Nunn P. Viewpoint TB diagnostics: What does the world really need? J Infect Dis. 2011;204(SUPPL):4.
6.
go back to reference UNitaid. Diagnostics Technology Landscape 5th Edition, May 2017. 2017. UNitaid. Diagnostics Technology Landscape 5th Edition, May 2017. 2017.
7.
go back to reference Bai Y, Wang Y, Shao C, Hao Y, Jin Y. GenoType MTBDRplus assay for rapid detection of multidrug resistance in mycobacterium tuberculosis: a meta-analysis. PLoS One. 2016;11:1–20. Bai Y, Wang Y, Shao C, Hao Y, Jin Y. GenoType MTBDRplus assay for rapid detection of multidrug resistance in mycobacterium tuberculosis: a meta-analysis. PLoS One. 2016;11:1–20.
8.
11.
go back to reference Ministry of health and Social welfare. Manual for the Management of Tuberculosis and Leprosy; 2013. p. 1–215. Ministry of health and Social welfare. Manual for the Management of Tuberculosis and Leprosy; 2013. p. 1–215.
15.
go back to reference GLI. TB Specimen Referral Systems and Integrated Networks. 2016. GLI. TB Specimen Referral Systems and Integrated Networks. 2016.
16.
go back to reference NTLP. United Republic of Tanzania Ministry of Health and Social Welfare National Tuberculosis and Leprosy Programme Manual for the Management of Tuberculosis and Leprosy SIxth Edition. 2013. NTLP. United Republic of Tanzania Ministry of Health and Social Welfare National Tuberculosis and Leprosy Programme Manual for the Management of Tuberculosis and Leprosy SIxth Edition. 2013.
17.
go back to reference NTLP. THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE National Strategic Plan V for Tuberculosis and Leprosy Programme. 2015. NTLP. THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE National Strategic Plan V for Tuberculosis and Leprosy Programme. 2015.
18.
go back to reference WHO. Global WHO Tuberculosis Report 2016. 13th ed. Switzerland: WHO Library Cataloguing-in-Publication Data; 2016. WHO. Global WHO Tuberculosis Report 2016. 13th ed. Switzerland: WHO Library Cataloguing-in-Publication Data; 2016.
Metadata
Title
Reducing delays to multidrug-resistant tuberculosis case detection through a revised routine surveillance system
Authors
Basra Esmail Doulla
Stephen Bertel Squire
Eleanor MacPherson
Esther Stanslaus Ngadaya
Beatrice Kemilembe Mutayoba
Ivor Langley
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05298-8

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.